Thomas S. Ray | |
---|---|
![]() Ray in 2011 | |
Born | |
Alma mater | Florida State University Harvard University |
Occupation(s) | Evolutionary biologist, computer scientist |
Known for | Tierra, skototropism |
Thomas S. Ray is an evolutionary biologist known for his research in tropical biology, digital evolution, and the human mind.
Ray earned his undergraduate degrees in biology and chemistry at Florida State University. He then proceeded to Harvard University, where he received his master's and Doctorate in Biology, specializing in plant behavior.
Ray began his career as a member of the Society of Fellows at the University of Michigan at Ann Arbor, and in 1981 joined the faculty of the University of Delaware's School of Life and Health Sciences. In 1993 he received a joint appointment in Computer and Information Science at U. Delaware while also being appointed to the External Faculty of the Santa Fe Institute.
In August 1993 he started a position as an invited researcher in the Advanced Telecommunications Research Institute International's Human Information Processing Research Labs Evolutionary Systems Department.
In 1998 Ray became a Professor in the Zoology (later Biology) & Computer Science departments at the University of Oklahoma. Ray retired from the University of Oklahoma in 2021.
Throughout his career he has studied different disciplines:
From 1974 to 1989, Ray worked as a tropical biologist, studying the evolution, ecology, and natural history of various organisms inhabiting rain forests. His research primarily focused on the foraging behavior of vines in the Araceae family, but also included studies on ants, butterflies, and beetles . Ray conducted most of his field work in Costa Rica, where he established the Finca El Bejuco biological station in the northern lowland rain forests. He continues to own and operate this station and remains deeply involved in rain forest conservation in Costa Rica.
In 1990, Ray turned his attention to artificial life, exploring the outcomes of evolution by natural selection within digital computation . This work began with the creation of Tierra, a system in which self-replicating machine code programs evolve by natural selection. His work in this field has attracted significant media attention . In 2000, he implemented a new system called Virtual Life, building upon Evolved Virtual Creatures, a concept originally created by Karl Sims. In 2003, Ray collaborated with Ivan Tanev to further develop the Virtual Life project.
The research conducted by T.S. Ray has substantially contributed to our understanding of the human mind, consciousness, and the effects of psychoactive substances. He has hypothesized that the human mind is composed of "mental organs," which are populations of neurons bearing a specific G-protein-coupled receptor (GPCR) (and other metabotropic receptors) on their surface. These mental organs are thought to provide a direct link between mental properties—such as joy, consciousness, and reason—and the genes and regulatory elements associated with GPCR. Importantly, because there is heritable genetic variation associated with these mental organs, they can evolve over time.
Ray's studies on psychedelic drugs have further elaborated on this theory. His research posits that the diverse effects of these substances can be attributed to their interactions with different mental organs. The breadth of these interactions is significant, with psychoactive substances showing activity across a wide range of receptor sites. This interaction pattern supports the idea that the diversity in effects of these drugs is likely due to their diverse interactions with different mental organs, emphasizing the roles of dozens of different receptors.
The theory also offers a fresh perspective on the effects of MDMA, a drug that is known for its unique entactogenic mental state. Traditional views suggest that MDMA's effects are primarily due to neurotransmitter release, especially serotonin. However, Ray proposes an alternative hypothesis: the distinctive mental state caused by MDMA arises from the simultaneous direct activation of imidazoline-1 (I1) and serotonin-2 (5-HT2) receptors, which correspond to specific mental organs. According to this theory, a mental organ can only enter consciousness if two things occur: the mental organ is directly activated at its defining receptor, and 5-HT2 is simultaneously activated.
To test these hypotheses, Ray has proposed the "primer/probe" method . A "primer" is a drug that selectively activates certain serotonin receptors, while a "probe" is a drug that activates a non-serotonin receptor corresponding to the mental organ that researchers want to bring into consciousness for study. By using both a primer and a probe, it is possible to load a mental organ into consciousness and thus study its role in the mind.
Taken together, this body of research provides an innovative framework for understanding the human mind, consciousness, and the effects of psychoactive substances, suggesting a direct linkage between mental properties, neuronal structures, and genetic components .
Currently, Ray is the scientific founder of Mindstate Design Labs, where his research revolves around psychoactive drugs as tools for probing the chemical architecture of the human mind. He proposes the existence of "mental organs", defined as populations of neurons bearing specific neurotransmitter receptors on their surface. Ray's work aims to use the diversity of mental organs to discover, design, and create diverse mental states.
Over the years, Ray has held several academic positions. In 1981, he joined the faculty of the University of Delaware, School of Life and Health Sciences. In 1993, he received a joint appointment in Computer and Information Science at the University of Delaware and was appointed to the External Faculty of the Santa Fe Institute. Later that year, he joined the Evolutionary Systems Department at ATR (Advanced Telecommunications Research Institute International Human Information Processing Research Labs in Japan as an invited researcher. In August 1998, he became a Professor of Zoology (later Biology) at the University of Oklahoma, with an adjunct appointment as a Professor of Computer Science.
Tierra is a computer program developed by Dr. Thomas S. Ray in the early 1990s. This innovative software allowed computer programs to compete for time (central processing unit (CPU) time) and space (access to main memory). Within the Tierra virtual machine, these computer programs are evolvable and capable of self-replicating and recombining. The virtual machine of Tierra is written in C and operates on a custom machine instruction set designed to facilitate code changes and reordering, featuring elements such as "jump to template" as opposed to the relative or absolute jumps common to most instruction sets.
The Tierra model has been utilized to explore the fundamental processes of evolutionary and ecological dynamics in a computational environment. It facilitates the investigation of processes such as the dynamics of punctuated equilibrium, host-parasite co-evolution, and density-dependent natural selection. Unlike more conventional models of evolutionary computation, such as genetic algorithms, Tierra does not have an explicit, or exogenous, fitness function built into the model. The fitness function in Tierra is endogenous, with survival and death being the core factors determining the "fitness" of a program, resulting in an instance of natural selection.
According to Ray and other researchers, this setup might allow for more "open-ended" evolution, in which the feedback dynamics between evolutionary and ecological processes can change over time. However, this claim is yet to be realized. Like other digital evolution systems, Tierra eventually reaches a point where novelty ceases to be created, and the system at large either begins looping or ceases to 'evolve'. The challenge of implementing true open-ended evolution in an artificial system is an ongoing question in the field of artificial life.
Researchers Mark Bedau and Norman Packard developed a statistical method of classifying evolutionary systems. In 1997, they applied these statistics to Evita, an artificial life model like Tierra and Avida, concluding that Tierra-like systems do not exhibit the open-ended evolutionary signatures of naturally evolving systems. Similarly, Russell K. Standish measured the informational complexity of 'organisms' within Tierra and did not observe complex growth in their evolution.
Ray was born in Norman Oklahoma. He has a daughter named Ariel Ivy Ray who was born in 1993.
Strong, D. R. and T. S. Ray. 1975. Host tree location behavior of a tropical vine (Monstera gigantea) by skototropism. Science, 190: 804–06.
Ray, T. S., and C. C. Andrews. 1980. Antbutterflies: Butterflies that follow army ants to feed on antbird droppings. Science 210: 1147–1148.
Ray, T. S. 1980. Syngonium oduberi (Araceae): A new species from the Osa Peninsula of Costa Rica. Aroideana 3(4): 128–129.
Ray, T. S. 1983. Monstera tenuis. In D. Janzen [ed.], Costa Rican natural history, 278–80. University of Chicago Press.
Ray, T. S. 1985. The host plant, Erythroxylum (Erythroxylaceae), of Agrias (Nymphalidae). J. Lep. Soc. 39(4):266–267.
Ray, T. S. 1988. Diversification of growth habits in the Araceae. Amer. J. Bot.76(Suppl.): 276.
Ray, T. S. 1990. Metamorphosis in the Araceae. Amer. J. Bot. 77(12): 1599–1609.
Ray, T. S. 1991. Evolution and optimization of digital organisms. In: Billingsley K. R., E. Derohanes, H. Brown, III [eds.], Scientific Excellence in Supercomputing: The IBM 1990 Contest Prize Papers, Athens, GA, 30602: The Baldwin Press, The University of Georgia. Publication date: December 1991, Pp. 489–531.
Ray, T. S. 1991. An approach to the synthesis of life. In : Langton, C., C. Taylor, J. D. Farmer, & S. Rasmussen [eds], Artificial Life II, Santa Fe Institute Studies in the Sciences of Complexity, vol. XI, 371–408. Redwood City, CA: Addison-Wesley. ,
Ray, T. S. 1992. Foraging behaviour in tropical herbaceous climbers (Araceae). Journal of Ecology 80: 189–203.
Ray, T. S. 1994. An evolutionary approach to synthetic biology: Zen and the art of creating life. Artificial Life 1(1/2): 195–226. Reprinted In: Langton, C. G. [ed.], Artificial Life, an overview. The MIT Press, 1995.
Ray, T. S. 1994. Evolution, complexity, entropy, and artificial reality. Physica D 75: 239–263.
Thearling, Kurt, and Thomas S. Ray. 1997. “Evolving Parallel Computation,” Complex Systems, 10(3):229–237. (June 1996)
Ray, T. S. 1998. Selecting Naturally for Differentiation: preliminary evolutionary results. Complexity, 3(5): 25–33. John Wiley & Sons, Inc.
Ray, T. S. 2001. Aesthetically Evolved Virtual Pets. Leonardo 34(4): 313–316.
Ray, T. S. 2002. Kurzweil’s Turing Fallacy. In: Jay Wesley Richards [ed.]. “Are We Spiritual Machines?: Ray Kurzweil vs. the Critics of Strong AI”, with George Gilder, Ray Kurzweil, William Dembski, John Searle, Michael Denton and Thomas Ray. Discovery Institute, Seattle. Pp. 116–127.
Ray, T.S. 2010. Psychedelics and the Human Receptorome. PLoS ONE. , February 2, 2010.
Ray, T. S. 2012. Mental Organs and the Origins of Mind. In: L. Swan (Ed) Origins of Mind, pp. 301–326. New York / Heidelberg: Springer.
Ray, T. S. 2015. Constructing the ecstasy of MDMA from its component mental organs: Proposing the primer/probe method. Medical Hypotheses / Elsevier, 87, 48 – 60.
Ray, T.S. 2017. Mental Organs and the Breadth and Depth of Consciousness. Transform Press. June 27, 2017.
3,4-Methyl
Psychopharmacology is the scientific study of the effects drugs have on mood, sensation, thinking, behavior, judgment and evaluation, and memory. It is distinguished from neuropsychopharmacology, which emphasizes the correlation between drug-induced changes in the functioning of cells in the nervous system and changes in consciousness and behavior.
Psychedelics are a subclass of hallucinogenic drugs whose primary effect is to trigger non-ordinary mental states and a perceived "expansion of consciousness". Also referred to as classic hallucinogens or serotonergic hallucinogens, the term psychedelic is sometimes used more broadly to include various types of hallucinogens, such as those which are atypical or adjacent to psychedelia like salvia and MDMA, respectively.
An altered state of consciousness (ASC), also called an altered state of mind, altered mental status (AMS) or mind alteration, is any condition which is significantly different from a normal waking state. It describes induced changes in one's mental state, almost always temporary. A synonymous phrase is "altered state of awareness".
Tierra is a computer simulation developed by ecologist Thomas S. Ray in the early 1990s in which computer programs compete for time and space. In this context, the computer programs in Tierra are considered to be evolvable and can mutate, self-replicate and recombine. Tierra's virtual machine is written in C. It operates on a custom instruction set designed to facilitate code changes and reordering, including features such as jump to template.
Empathogens or entactogens are a class of psychoactive drugs that induce the production of experiences of emotional communion, oneness, relatedness, emotional openness—that is, empathy or sympathy—as particularly observed and reported for experiences with 3,4-methylenedioxymethamphetamine (MDMA). This class of drug is distinguished from the classes of hallucinogen or psychedelic, and amphetamine or stimulants. Major members of this class include MDMA, MDA, MDEA, MDOH, MBDB, 5-APB, 5-MAPB, 6-APB, 6-MAPB, methylone, mephedrone, GHB, αMT, and αET, MDAI among others. Most entactogens are phenethylamines and amphetamines, although several, such as αMT and αET, are tryptamines. When referring to MDMA and its counterparts, the term MDxx is often used. Entactogens are sometimes incorrectly referred to as hallucinogens or stimulants, although many entactogens such as ecstasy exhibit psychedelic or stimulant properties as well.
3,4-Methylenedioxyamphetamine (MDA), sometimes referred to as “sass,” is an empathogen-entactogen, stimulant, and psychedelic drug of the amphetamine family that is encountered mainly as a recreational drug. In its pharmacology, MDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA). In most countries, the drug is a controlled substance and its possession and sale are illegal.
α-Ethyltryptamine, also known as etryptamine, is an entactogen and stimulant drug of the tryptamine family. It was originally developed and marketed as an antidepressant under the brand name Monase by Upjohn in the 1960s before being withdrawn due to toxicity.
MBDB, also known as N-methyl-1,3-benzodioxolylbutanamine or as 3,4-methylenedioxy-N-methyl-α-ethylphenylethylamine, is an entactogen of the phenethylamine, amphetamine, and phenylisobutylamine families related to MDMA. It is known by the street names "Eden" and "Methyl-J".
5-MeO-MiPT is a psychedelic and hallucinogen of the tryptamine family. It used by some as an entheogen. It has structural and pharmacodynamic properties similar to the drugs 5-MeO-DiPT, DiPT, and MiPT. It is commonly used as a "substitute" for 5-MeO-DiPT because of the very similar structure and effects.
Neuropsychopharmacology, an interdisciplinary science related to psychopharmacology and fundamental neuroscience, is the study of the neural mechanisms that drugs act upon to influence behavior. It entails research of mechanisms of neuropathology, pharmacodynamics, psychiatric illness, and states of consciousness. These studies are instigated at the detailed level involving neurotransmission/receptor activity, bio-chemical processes, and neural circuitry. Neuropsychopharmacology supersedes psychopharmacology in the areas of "how" and "why", and additionally addresses other issues of brain function. Accordingly, the clinical aspect of the field includes psychiatric (psychoactive) as well as neurologic (non-psychoactive) pharmacology-based treatments. Developments in neuropsychopharmacology may directly impact the studies of anxiety disorders, affective disorders, psychotic disorders, degenerative disorders, eating behavior, and sleep behavior.
Sex and drugs refers to the influence of substances on sexual function and experience. Sex and drugs date back to ancient humans and have been interlocked throughout human history. Sexual performance is known as the execution of the act of sex and the quality of sexual activity. This includes elements such as libido, sexual function, sensation. Drugs are termed as any chemical substance that produces a physiological and or psychological change in an organism. Drugs categorized as psychoactive drugs, antihypertensive drugs, antihistamines, cancer treatment, and hormone medication have a significant impact on sexual performance. Various drugs result in different effects, both positive and negative. Negative effects may include low libido, erection issues, vaginal dryness and anorgasmia. Positive effects usually address these issues, overall enhancing sexual performance and contributing to a more enjoyable sexual experience. It is crucial to know that the impact of drugs on sexual performance varies among individuals, especially among different genders.
Ariadne, also known chemically as 4C-D or 4C-DOM, by its developmental code name BL-3912, and by its former tentative brand name Dimoxamine, is a little-known psychoactive drug of the phenethylamine, amphetamine, and phenylisobutylamine families. It is a homologue of the psychedelics 2C-D and DOM.
MDAI, also known as 5,6-methylenedioxy-2-aminoindane, is an entactogen drug of the 2-aminoindane group which is related to MDMA and produces similar subjective effects.
A serotonin releasing agent (SRA) is a type of drug that induces the release of serotonin into the neuronal synaptic cleft. A selective serotonin releasing agent (SSRA) is an SRA with less significant or no efficacy in producing neurotransmitter efflux at other types of monoamine neurons, including dopamine and norepinephrine neurons.
UWA-101 is a phenethylamine derivative researched as a potential treatment for Parkinson's disease. Its chemical structure is very similar to that of the illegal drug MDMA, the only difference being the replacement of the α-methyl group with an α-cyclopropyl group. MDMA has been found in animal studies and reported in unauthorised human self-experiments to be effective in the short-term relief of side-effects of Parkinson's disease therapy, most notably levodopa-induced dyskinesia. However the illegal status of MDMA and concerns about its potential for recreational use, neurotoxicity and potentially dangerous side effects mean that it is unlikely to be investigated for medical use in this application, and so alternative analogues were investigated.
Artificial life is a field of study wherein researchers examine systems related to natural life, its processes, and its evolution, through the use of simulations with computer models, robotics, and biochemistry. The discipline was named by Christopher Langton, an American computer scientist, in 1986. In 1987, Langton organized the first conference on the field, in Los Alamos, New Mexico. There are three main kinds of alife, named for their approaches: soft, from software; hard, from hardware; and wet, from biochemistry. Artificial life researchers study traditional biology by trying to recreate aspects of biological phenomena.
Evolutionary models of drug use seek to explain human drug usage from the perspective of evolutionary fitness. Plants for instance, may provide fitness benefits by relieving pain. Proponents of this model of drug use suggest that the consumption of pharmacological substances for medicinal purposes evolved in the backdrop of human-plant coevolution as a means of self-medication. Humans thus learned to ignore the cues of plant toxicity because ingesting the bioactive compounds of plants in small amounts was therapeutic.
(R)-3,4-Methylenedioxy-N-methylamphetamine ((R)-MDMA), also known as (R)-midomafetamine or as levo-MDMA, is the (R)- or levorotatory (l-) enantiomer of 3,4-methylenedioxy-N-methylamphetamine (MDMA; midomafetamine; "ecstasy"), a racemic mixture of (R)-MDMA and (S)-MDMA. Like MDMA, (R)-MDMA is an entactogen or empathogen. It is taken by mouth.